PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced that its innovative cancer therapy, CTIM-76, will be featured at the upcoming Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting in Houston, Texas. The meeting is scheduled from November 8 to 10, 2024, at the George R. Brown Convention Center.
The presentation will focus on determining the first in-human dose of CTIM-76, a pioneering Claudin 6 x CD3 bispecific antibody designed to redirect T cells. This promising therapy targets Claudin 6, a protein prevalent in a variety of solid tumors such as ovarian, endometrial, lung, gastric, and testicular cancers.
The poster presentation, authored by Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, and Eric Butz, is set for November 9, 2024, at 9:00 a.m. CDT in Exhibit Halls AB. This presentation will provide valuable insights into the development and potential impact of CTIM-76.
CTIM-76 is notable for its potential to offer convenient dosing with a low risk of immune response and scalable production, which could make it a viable option for a large number of cancer patients. Preclinical studies indicate that this therapy could significantly enhance treatment options for those battling solid tumors.
Context Therapeutics’ involvement in the SITC Annual Meeting highlights the company’s efforts to advance cancer treatment and improve patient outcomes through innovative therapies like CTIM-76.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.